Cutaneous Lupus Erthyematosus and Anti-TNF-α Therapy: A Case Report With Review of the Literature
October 2010 | Volume 9 | Issue 10 | Case Report | 1283 | Copyright © 2010
Danielle Levine MD, Stephen A. Switlyk MD, Alice Gottlieb MD PhD
Anti-tumor necrosis factor-α (TNF-α) immunotherapy is revolutionizing the treatment of immune disease, particularly Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and psoriasis. The role of anti-TNF-α agents in the management of cutaneous lupus erythematosus (LE), however, is not as clear. While experimental reports have suggested a potential benefit of anti-TNF-α therapy in severe cutaneous LE, newer reports have identified these medications as instigators or exacerbators of the disease. In this review, the authors present a case of a patient whose persistent discoid LE (DLE) was exacerbated by a trial of adalimumab, one of the currently available TNF-α-blocking agents. The authors review 128 cases in the literature in which anti-TNF-α therapy was implicated in cutaneous LE pathogenesis, with emphasis on DLE, and consider a number of mechanisms whereby this arguably paradoxical effect may occur. The authors then propose possible approaches to the management of anti-TNF-α therapy-induced cutaneous LE.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close